Glycogen Synthase Kinase 3Β (Gsk 3Β) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Glycogen synthase kinase-3 beta (GSK-3β) is a serine/threonine protein kinase that plays a central role1 in energy
metabolism, neuronal cell development, and circadian rhythm regulation. It is one of the most important kinases in the brain and is critically involved in the pathogenesis of
Alzheimer's Disease and other neurodegenerative disorders12.
¶ Gene and Protein
- Gene Symbol: GSK3B
- Chromosomal Location: 3q13.33
- Protein Family: CMGC serine/threonine protein kinases
- Molecular Weight: 47 kDa
GSK-3β is a proline-directed serine/threonine kinase consisting of:
- N-terminal regulatory domain
- Catalytic kinase domain
- C-terminal regulatory domain
The kinase has two isoforms: GSK-3α (51 kDa) and GSK-3β (47 kDa), encoded by different genes but sharing 97% sequence homology in their catalytic domains.
- Phosphorylates and inhibits glycogen synthase
- Regulates glucose homeostasis
- Responds to insulin signaling
- Regulates synaptic plasticity
- Controls neuronal development
- Modulates circadian rhythm
- Regulates transcription factors
- Phosphorylates tau at multiple sites relevant to AD pathology
- Key sites: Ser9, Ser396, Ser404, Thr181, Thr231
GSK-3β is a major tau kinase3:
- Hyperphosphorylates tau at AD-relevant sites23
- Promotes tau aggregation
- Contributes to neurofibrillary tangle formation
- Activity is increased in AD brain
- Aβ increases GSK-3β activity
- Creates a vicious cycle between Aβ and tau pathology
- GSK-3β mediates Aβ-induced synaptic dysfunction
- Impairs long-term potentiation (LTP)
- Affects NMDA receptor signaling
- Promotes synaptic loss
Several classes of inhibitors have been developed:
- ATP-competitive inhibitors: Tideglusib, NP031112 (NP-12), CHIR99021
- Non-ATP-competitive inhibitors: VP0.7
- Natural compounds: Lithium, curcumin
- Tideglusib has been tested in Phase II clinical trials for AD
- Challenges include brain penetration and toxicity
The study of Glycogen Synthase Kinase 3Β (Gsk 3Β) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Avila J, Wandosell F, Hernández F. Role of glycogen synthase kinase-3 in Alzheimer's Disease pathogenesis. Curr Alzheimer Res. 2010;7(3):207-214.
- Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of Alzheimer's Disease. J Neurochem. 2008;104(6):1433-1439.
- Beurel E, Grieco SF, Jope RS. Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacol Ther. 2015;148:114-131.
- Lichtenstein MP, Carriba P, Baltrons MA, et al. Secreted amyloid precursor protein-alpha modulates ERK and AKT phosphorylation. J Mol Neurosci. 2010;41(1):146-157.
- Medina M, Avila J. Glycogen synthase kinase-3 (GSK-3) and its physiological importance in the brain: more than just a co-incidence detector. J Neural Transm Suppl. 2014;78(7):1009-1015.
- Cruz JC, Tsai LH. A Jekyll and Hyde role of cyclin-dependent kinase 5 in brain development and disease. Genes Dev. 2004;18(24):2937-2940.
- Lucas JJ, Hernández F, Gómez-Ramos P, et al. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 2001;20(1-2):27-39.
- Sereno L, Coma M, Rodríguez M, et al. A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. Neurobiol Dis. 2009;35(3):359-367.
- Forlenza OV, De-Paula VJ, Diniz BS. Neuroprotective effects of lithium: implications for the treatment of Alzheimer's Disease and related neurodegenerative disorders. Curr Alzheimer Res. 2014;11(2):189-198.
- Golpich M, Amini E, Hemmati F, et al. Glycogen synthase kinase-3 beta signaling: Implications for Parkinson's Disease. Pharmacol Res. 2015;97:16-26.
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
10 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
50% |
Overall Confidence: 31%